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1Abbott Laboratories UK, Maidenhead, Berkshire, UK; 2MAPI Values
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OBJECTIVE: NICE is currently developing clinical guidelines on
nutritional support in adults. The objective of this study was to
determine which patients in primary care in the UK were pre-
scribed enteral nutrition (sip & tube feeds) and to examine the
associated economic outcomes. METHODS: Patients prescribed
enteral nutrition during 2000/2001 were identiﬁed from the
General Practice Research Database (GPRD). The results were
analysed according to pre-determined BMI categories and diag-
nostic categories (cancer, dysphagia, stroke, GI, neurological,
respiratory disorders, cystic ﬁbrosis, renal disease, feeding difﬁ-
culties). Results for the two largest diagnostic groups (GI disor-
ders and cancer) are presented. RESULTS: In all, 2.34 million
patients were registered on GPRD. 13,153 patients (0.6%)
received >1 prescriptions for enteral nutrition, of whom 1332
had a recorded height and weight measurement. In all, 83% of
patients with GI disorders and 69% with cancer had a BMI
below 25. The number of nutritional prescriptions as a percent-
age of the total prescriptions by primary diagnosis category
(cancer and GI disorders respectively) were as follows: BMI
15–<20 (1.1%, 3.0%), 21–<25 (3.2%, 2.1%), 26–<30 (1.2%,
0.3%) and 31–<40 (0.5%, 0.4%). GP visits were frequent in
both diagnostic groups in all BMI categories (mean range 27–36
for GI disorders; 38–59 for cancer). Hospitalisations were also
frequent with means ranging from 2.5–3.0 for GI disorders;
1.9–4.6 for cancer, possibly reﬂecting severity of disease. CON-
CLUSIONS: It is expected that patients with a lower BMI would
have a higher percentage of nutritional prescriptions. Whilst this
was found to be the case for patients with GI disorders, the study
results showed that patients with cancer and a low BMI had
fewer nutritional prescriptions. This suggests that some patients
in the community who could beneﬁt from enteral nutrition may
not be receiving it.
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OBJECTIVES: No clinical guidelines or economic data exist on
the use of enteral nutrition (EN) for the UK. The aim of this
study was to determine which patients receive EN, and to 
estimate the relative economic burden of EN in the clinical 
management of such patients using observational databases.
METHODS: GPRD and CHKS datasets contain aggregated,
anonymised information on diagnoses, patient demographics
and resource use data in primary care (GPRD) and secondary
care (CHKS) settings. CHKS covered over 80 million episodes in
2001, representing 55% of UK hospitalisations. An average of
2,342,000 people were registered in the GPRD database in
2000/2001 representing 3.4% of the UK population. Patients
were identiﬁed using EN procedure OPCS-4 codes (CHKS) and
tube and sip feed drug codes (GPRD). Both databases were
analysed for comorbidities and resource use. RESULTS: From
the GPRD database (2000/2001), 13,153 patients received EN
of whom 1332 had a recorded height and weight measurement.
In the CHKS database there were 15,728 admissions in 2001
(<0.1% of all UK hospitalisations). Main diagnoses in both set-
tings were dysphagia, cancer, stroke, feeding difﬁculties and
anorexia and gastrointestinal disorders. Resource consumption
was high. The mean number of hospitalisations per patient was
2.24 and the mean number of nutritional prescriptions (tube and
sip feeds) annually in primary care was 5.8. However, the costs
of daily tube feeds (£10.20–£13.18) represented less than 4% 
of daily inpatient costs. CONCLUSIONS: Although 40% of
patients in UK hospitals and 11% in the community are mal-
nourished, very few are nutritionally assessed in order to receive
EN. The economic burden of EN remains low compared to the
overall patient management. This is also one of the ﬁrst obser-
vational database studies which has aimed to estimate resource
use across both primary and secondary care settings.
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THE INFLUENCE OF CHANGE OF CO-PAYMENT TO THE USE
OF ANTIBIOTIC AGENTS
Szalayova A
Ministry of Health, Bratislava, Slovak Republic
Increased expenditures for pharmaceuticals in previous years
lead to implementation of several cost-containment measures in
2003 in the Slovak Republic. Within that, co-payments for
antibiotic drugs were increased from 0 to 1.25€ per package in
2002 and in the beginning of 2003 from 0 to 5€ per package
after November, 2003. The consumption of antibiotics signiﬁ-
cantly decreased from November 2003 compared to the same
period the previous year. OBJECTIVES: To assess the inﬂuence
of increased co-payment of antibiotic agents to their decreased
consumption in a retrospective study. METHODS: Consumption
of antibiotic agents (group J01 according to ATC classiﬁcation)
prescribed in outpatient care in the Slovak Republic during the
period of November, 2003 to April, 2004 was compared to con-
sumption during November, 2002 to April, 2003. Antibiotics
were divided into three groups according to the level of co-
payment: without increased co-payment, with slightly increased
and signiﬁcantly increased co-payment. RESULTS: Overall con-
sumption in period 2003–2004 decreased by 25.1% compared
to the previous year. Consumption was 46.5% lower in the
group with the highest increase of co-payment, but only 30.9%
or 13.8% lower in the group with slightly increased co-payment
and in the group without change in co-payment, respectively.
CONCLUSIONS: Increase in co-payment in November, 2003
had a huge effect on the use of antibiotic agents in the Slovak
Republic. Although 55% of antibiotic agents had no change in
the level of co-payment, the consumption decreased in this group
by 13.8%, probably because of awareness of increased co-
payments within this group of pharmaceuticals.
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USE OF PATIENT-REPORTED OUTCOMES IN EVALUATION OF
HEART FAILURE DEVICE THERAPY: THE REGULATORY
PERSPECTIVE
Muni NI1, Pocock S2, Berman MR1,Yue LQ1
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OBJECTIVES: The FDA is tasked with the evaluation of medical
devices to determine the products’ safety and effectiveness. Uti-
lization of patient-reported outcome (PRO) measures for medical
device therapies poses special methodological challenges, due to
small sample sizes and the often unblinded study design of device
clinical trials. However, PRO’s might prove useful in special cir-
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cumstances to assist the Agency’s determination of device safety
and effectiveness. One example is left ventricular assist device
(LVAD) therapy for end-stage heart failure. METHODS: Clini-
cal trials conducted in support of LVAD regulatory approval
have demonstrated mortality beneﬁts compared to optimal
medical therapy alone. However, signiﬁcant adverse events are
also typically observed, including sepsis, bleeding and stroke.
The regulatory challenge is to determine an acceptable tradeoff
between mortality and adverse events. In this regard, PRO’s
including quality of life measures could provide additional infor-
mation to assist in decision-making for device approval and 
also guide development of a more informative product label.
RESULTS: Three issues need to be addressed to boost the scien-
tiﬁc validity of PRO’s in heart failure device trials: 1) the inher-
ent unblinded study design for such devices makes PRO’s
susceptible to patient bias, confounding study results; 2) differ-
ential rates of follow-up between treatment arms: patients too
moribund to complete follow-up assessment tools might lead to
underreporting of negative HRQOL data and confound study
results; and 3) a consensus needs to be achieved regarding the
selection of valid assessment tools for heart failure studies. CON-
CLUSIONS: PRO’s have promise in heart failure device evalua-
tion, however, several important issues need to be addressed to
properly incorporate such measures in studies intended for reg-
ulatory approval. The FDA welcomes dialogue with the clinical,
academic and industry communities to develop appropriate PRO
measures for heart failure device therapy.
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SELF-EFFICACY AND ACADEMIC ACHIEVEMENT OF THE
FIFTH YEAR PHARMACY STUDENTS OF CHULALONGKORN
UNIVERSITY, 2003
Auamnoy T, Mekaroonreung S,Techawatcharatep C
Chulalongkorn University, Bangkok,Thailand
OBJECTIVES: To predict students’ academic achievement (GPA)
by Self-efﬁcacy (SE). SE is deﬁned as the self-perception that one
can master a certain task or perform adequately in a given situ-
ation. METHODS: A descriptive cross-sectional survey was
employed for studying the relationship between Self-efﬁcacy and
academic achievement (GPA) of all (178) 5th year pharmacy stu-
dents at The College of Pharmacy, Chulalongkorn University,
Bangkok, Thailand during the period of August to September,
2003. RESULTS: The ﬁnal return rate of questionnaire was 171
(96.06%). The respondents average age was 22.02 years. Most
(124) were female (72.51%). The reliability coefﬁcient (Cron-
bach’s alpha) of Self-Efﬁcacy (SE) scale was 0.87. The ﬁndings
showed that there was positive relationship between SE and aca-
demic achievement (GPA) r = 0.38 (p = 0.03). The length of time
for preparing for an examination by a female was longer than
for a male (p = 0.03). There was no difference between male and
female SE (p = 0.07). However, female’s GPA was signiﬁcantly
higher than male’s (p = 0.02). SE of the Bangkoker students was
not different form the Non-Bangkoker students (p = 0.87). Stu-
dents who participated in activities had higher SE than students
who did not (p = 0.24) but the GPA of the two groups was not
different (p = 0.59). Attitude toward pharmacy profession had
no impact on SE nor GPA (p = 0.78, 0.82). The three predictors
of the model were SE, Gender, and Time (to prepare the exam-
ination) R square = 0.40, beta = 0.38, 0.10, and 0.07 (p = 0.02).
IQ was not controlled in this study. CONCLUSIONS: Self-Efﬁ-
cacy was a good predictor of academic achievement of Chula-




OBESITY AND THE RISK OF UPPER RESPIRATORY 
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OBJECTIVES: High Body Mass Index (BMI) and obesity, preva-
lent throughout industrialised societies, are known to be associ-
ated with many co-morbidities. A possible increase in upper
respiratory tract infections (URTI) associated with higher BMI
was investigated in this study. METHODS: Cohort study using
prospectively recorded patient data within the Full Feature
General Practice Research Database (GPRD) which represents
approximately 5% of UK population. Study subjects were cate-
gorised according to their baseline BMI into ﬁve exposure
groups: I 18.5–24.9; II 25.0–29.9; III 30.0–34.9; IV 35.0–39.9
and V 40.0 and above. BMI records of 50.0 and over were 
discarded. Patients were followed from January 1, 1998 until
December 31, 2002. Study outcomes were either Ear Nose and
Throat (ENT) infections, or Respiratory Tract Infections (RTI).
Statistical analysis: For each outcome group, crude incidence
rates and incidence rate ratios (IRR) by BMI category were esti-
mated. Poison regression analysis was used to make adjustments
for age, gender, asthma, COPD, diabetes, smoking status, GP
consultations and sleep apnoea. RESULTS: A total of 244,479
patients were eligible for the cohort. The adjusted IRR for ENT
infections and URTI respectively was for BMI group II, 1.13
(1.11, 1.15) and 1.10 (1.08, 1.12), for BMI group III, 1.18 (1.15,
1.21) and 1.21 (1.17, 1.24) BMI group IV, 1.23 (1.17, 1.28) and
1.33 (1.27, 1.39) and for BMI group V 1.29 (1.20, 1.38) and
1.42 (1.32, 1.53). These ﬁndings were consistent after stratiﬁca-
tion by the number of GP consultations in 1997. CONCLU-
SIONS: This study provides evidence that there is an association
between increasing BMI and ENT and upper respiratory tract
infection. This association should be taken into consideration in
the evaluation of the burden of obesity.
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SOCIAL COST OF OVERWEIGHT AND OBESITY:
SPESA STUDY
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OBJECTIVE: In Italy, the most recent report for the National
Institute of Statistics (ISTAT) indicate that 1/3 of Italians are
overweight an 1/10 obese, making the problem less dramatic
than in the UK, Germany or USA. The objectives of this prospec-
tive naturalistic study were to describe direct and indirect costs
attributable to the management of overweight and obesity and
to identify factors associated with costs of management of 
subjects with overweight and obese. METHODS: The study
included subjects between 18–65 years old with a body mass
index greater than 25 (BMI, deﬁned as weight in kilograms
divided by the square of height in meters). Our estimates of the
direct Health Care costs for the Italian National Health Care
Service (I-Nhs) refer to 399 subjects enrolled at 52 centers and
show a signiﬁcant increase in total and I-Nhs monthly costs with
increasing BMI. RESULTS: The increase in the average total
monthly costs between overweight (82€), mild (189€), moderate
(197€) and severe (233€) obese subjects was borderline signiﬁ-
cant (P = 0.051, Kruskall Wallis test). The increase in the average
